Capricor Therapeutics

FDA
Biotech

Capricor secures reprieve as FDA extends DMD cell therapy review

The FDA deferred its decision to review information the biotech submitted after a negative advisory committee vote.
Nick Paul Taylor Aug 25, 2026 3:26am
pivot change turnaround direction walk away

Capricor soars on plan to amend DMD filing after adcomm setback

Aug 14, 2026 10:20am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

AstraZeneca adds FDA cell and gene veteran—Chutes & Ladders

Jun 5, 2026 8:30am
Go sign green light

FDA reconsidering Capricor’s snubbed DMD cell therapy

Mar 10, 2026 11:14am
dynamic arrows moving up

Capricor sets up 2nd DMD approval attempt with ph. 3 win

Dec 3, 2025 11:11am
Manila folder with CONFIDENTIAL printed on it in red

Capricor responds to cell therapy snub, disputes FDA’s concerns

Sep 9, 2025 11:44am